Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ilaria Bertoldi & Roberto Caporali. (2021) Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis. Open Access Rheumatology: Research and Reviews 13, pages 221-237.
Read now
Read now
Thomas El Jammal, Pascal Sève, Mathieu Gerfaud-Valentin & Yvan Jamilloux. (2021) State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. Expert Opinion on Pharmacotherapy 22:2, pages 205-218.
Read now
Read now
Ying-Ming Chiu & Der-Yuan Chen. (2020) Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Review of Clinical Immunology 16:2, pages 207-228.
Read now
Read now
Articles from other publishers (16)
Abdelmoujoud Faris, Ibrahim M. Ibrahim, Omkulthom Al kamaly, Asmaa Saleh & Menana Elhallaoui. (2023) Computer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors. Molecules 28:15, pages 5914.
Crossref
Crossref
Alyssa Torres, Sarah Kang, Christopher B. Mahony, Martha Cedeño, Patricia G. Oliveira, Marta Fernandez-Bustamante, Samuel Kemble, Teresina Laragione, Percio S. Gulko, Adam P. Croft, Elsa Sanchez-Lopez, Shigeki Miyamoto & Monica Guma. (2023) Role of mitochondria-bound HK2 in rheumatoid arthritis fibroblast-like synoviocytes. Frontiers in Immunology 14.
Crossref
Crossref
Krisztina Futosi, Boglárka Bajza, Dorottya Deli, András Erdélyi, Simon Tusnády & Attila Mócsai. (2023) Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors. Frontiers in Pharmacology 14.
Crossref
Crossref
Zhize Ye, Jinyu Hu, Jing Wang, Ya-nan Liu, Guo-xin Hu & Ren-ai Xu. (2023) The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism. Chemico-Biological Interactions 374, pages 110398.
Crossref
Crossref
Fei Liu, Bin Wang, Yanlong Liu, Wei Shi, Zhongyuan Hu, Xiayun Chang, Xujing Tang, Ying Zhang, Hongjiang Xu & Ying He. (2023) Design, synthesis and biological evaluation of novel N-(methyl-d) pyridazine-3-carboxamide derivatives as TYK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 86, pages 129235.
Crossref
Crossref
Juan M. Reyes, Magda V. Gutierrez‐Ardila, Hugo Madariaga, William Otero, Renato Guzman, Jorge Izquierdo, David J. Del Castillo, Mauricio Abello, Patricia Velez, Dario Ponce de Leon, Tatjana Lukic, Luisa F. Amador & Natalia Castaño. (2023) Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study. Health Science Reports 6:3.
Crossref
Crossref
Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao & Yi Zhun Zhu. (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Zhenwu Yang, Yujia Tian, Yue Kong, Yushan Zhu & Aixia Yan. (2022) Classification of JAK1 Inhibitors and SAR Research by Machine Learning Methods. Artificial Intelligence in the Life Sciences 2, pages 100039.
Crossref
Crossref
Yusuf Karabulut, Halise Hande Gezer, Selin Esen, İrfan Esen & Ali Rıza Türkoğlu. (2022) Tofacitinib monotherapy and erectile dysfunction in rheumatoid arthritis: a pilot observational study. Rheumatology International 42:9, pages 1531-1537.
Crossref
Crossref
Zixuan Zhao, Zhenglai Hua, Xinyi Luo, Yang Li, Liuchunyang Yu, Ming Li, Cheng Lu, Ting Zhao & Yuanyan Liu. (2022) Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomedicine & Pharmacotherapy 150, pages 113074.
Crossref
Crossref
Jianlin Zuo, Jinshuo Tang, Meng Lu, Zhongsheng Zhou, Yang Li, Hao Tian, Enbo Liu, Baoying Gao, Te Liu & Pu Shao. (2021) Glycolysis Rate-Limiting Enzymes: Novel Potential Regulators of Rheumatoid Arthritis Pathogenesis. Frontiers in Immunology 12.
Crossref
Crossref
Shunsuke Mori, Yukitomo Urata, Tamami Yoshitama & Yukitaka Ueki. (2021) Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis. RMD Open 7:2, pages e001601.
Crossref
Crossref
Liqiang Zhi, Jingqi Liang, Wei Huang, Jianbing Ma, Zhong Qing & Xi Wang. (2021) Circ_AFF2 facilitates proliferation and inflammatory response of fibroblast-like synoviocytes in rheumatoid arthritis via the miR-375/TAB2 axis. Experimental and Molecular Pathology 119, pages 104617.
Crossref
Crossref
Fernanda O. Novais, Ba T. Nguyen & Phillip Scott. (2021) Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis. Journal of Investigative Dermatology 141:3, pages 575-585.
Crossref
Crossref
Iordanis S. Mourouzis, Antonis S. Manolis & Constantinos Pantos. (2020) Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). Current Vascular Pharmacology 18:5, pages 455-462.
Crossref
Crossref
Shunsuke Mori & Yukitaka Ueki. (2019) Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clinical Rheumatology 38:12, pages 3391-3400.
Crossref
Crossref